Chromosome Interaction Detection for ALS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for diseases like amyotrophic lateral sclerosis (ALS) and Huntington's disease face challenges in data analysis due to varying levels of change, making it difficult to classify patient cohorts effectively, whereas chromosome conformation signatures (CCSs) provide a binary read-out that is more suitable for diagnostic and prognostic purposes.
Innovation Solution
A process is developed to detect chromosome interactions relevant to ALS or Huntington's disease by determining the presence or absence of specific chromosome interactions within defined disease-associated regions of the genome using the EpiSwitch™ system, which involves cross-linking chromosomal regions, subjecting them to cleavage, and ligating the nucleic acids to generate a ligated product for hybridization analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarkers (RNA expression patterns and protein markers) are used, then disease characteristics can be identified, but data analysis becomes difficult due to varying levels of change between patients
Solution Approach 1:
The patent changes the measurement parameter from continuous (varying levels of RNA expression and protein markers) to discrete (binary presence/absence of chromosome interactions). This transformation simplifies data analysis by converting complex continuous data into straightforward binary outcomes, directly resolving the contradiction between detection capability and analysis complexity.
2Ease of operation
If chromosome conformation signatures are used, then a binary read-out is achieved suitable for classification, but the method complexity increases compared to conventional biomarkers
Solution Approach 1:
The patent segments the genome into specific regions and detects chromosome interactions between these segments. By focusing on discrete chromosomal regions and their interactions rather than analyzing entire genomes or multiple continuous biomarkers, the method achieves binary classification results while managing complexity through targeted regional analysis.
3Loss of information
If continuum read-out biomarkers are used, then detailed molecular information is obtained, but classification statistics performance deteriorates due to magnitude variation between patients
Solution Approach 1:
The patent transforms the measurement parameter from continuous magnitude (amount of biomarker expression) to discrete presence/absence (chromosome interaction occurrence). This parameter change eliminates the reliability issue caused by magnitude variation between patients while preserving critical diagnostic information through the binary interaction state.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of specific chromosome interactions that are stable and indicative of disease subgroups, enabling early detection and personalized medicine by providing a binary read-out that is less variable between individuals, thus improving diagnostic and prognostic accuracy.
Implementation Method 1
which involves cross-linking chromosomal regions, subjecting them to cleavage, and ligating the nucleic acids
Implementation Method 2
contacting a first set of nucleic acids from subgroups with different states of the chromosome with a second set of index nucleic acids, and allowing complementary sequences to hybridise
Data Source
AI summary
A process for analysing chromosome regions and interactions relating to ALS and Huntington's disease.